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Abstract
Background: Multidrug resistance (MDR) is a clinically, highly relevant phenomenon. Under chemotherapy many
tumors show an increasing resistance towards the applied substance(s) and to a certain extent also towards other
agents. An important molecular cause of this phenomenon is an increased expression of transporter proteins. The
functional relationship between high expression levels and chemotherapy resistance makes these MDR and MRP
(MDR related protein) proteins to interesting therapeutic targets. We here wanted to systematically analyze,
whether these proteins are tumor specific antigens which could be targeted immunologically.
Results: Using the reverse immunology approach, 30 HLA-A2.1 restricted MDR and MRP derived peptides (MDP)
were selected. Stimulated T cell lines grew well and mainly contained activated CD8
+ cells. Peptide specificity and
HLA-A2.1 restriction were proven in IFN-g-ELISpot analyses and in cytotoxicity tests against MDP loaded target cells
for a total of twelve peptides derived from MDR-1, MDR-3, MRP-1, MRP-2, MRP-3 and MRP-5. Of note, two of these
epitopes are shared between MDR-1 and MDR-3 as well as MRP-2 and MRP-3. However, comparably weak
cytotoxic activities were additionally observed against HLA-A2.1
+ tumor cells even after upregulation of MDR
protein expression by in vitro chemotherapy.
Conclusions: Taken together, these data demonstrate that human T cells can be sensitised towards MDPs and
hence, there is no absolute immunological tolerance. However, our data also hint towards rather low endogenous
tumor cell processing and presentation of MDPs in the context of HLA-A2.1 molecules. Consequently, we conclude
that MDR and MRP proteins must be considered as weak tumor specific antigens-at least for colorectal carcinoma.
Their direct contribution to therapy-failure implies however, that it is worth to further pursue this approach.
Keywords: Multidrug resistance, therapy resistance, tumor antigens, colorectal cancer, T cell epitopes, immunother-
apy, reverse immunology
Background
Chemotherapy is, apart from resection and irradiation, the
most common form of cancer treatment [1]. Unfortu-
nately, many patients’ tumors acquire drug resistance,
including the classical multidrug resistance (MDR), during
or after this kind of therapy. Therefore, this resistance
against multiple even chemically and structurally unrelated
chemotherapeutic agents, after treatment with a single
drug, remains a major obstacle to overcome in the field of
cancer therapy [1-3]. There are many different mechan-
isms of acquiring resistance including mutation or overex-
pression of the drug’s targets as well as inactivation or
efflux of the drug itself [4]. In the case of drug efflux, the
MDR phenomenon is accompanied by the synthesis of P-
glycoprotein, a member of the ATP-binding cassette
(ABC) transporters. ABC transporters are channels or
pumps using the energy of ATP hydrolyzation to drive the
translocation of their substrates across membranes against
diffusion gradients [3,4]. Hence, this mechanism allows
cancer cells to survive cytotoxic or targeted therapies and
treatment fails. In the process of acquiring resistance and
onward, MDR proteins and MDR related proteins (MRP)
are expressed in high levels on the cell surface.
Active immunotherapeutic approaches, such as dendritic
cell [5,6] and peptide vaccinations [7,8] as well as passive
immunotherapy, especially the application of therapeutic
antibodies [9,10] have become indispensable as additional
therapeutic options for various cancer entities in the last
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mainly aim at the induction of cytotoxic T lymphocytes
(CTL) which have the potential to eliminate even bulky
tumor masses [14,15]. Yet, this ability raises concerns on
the risk of deleterious autoimmune phenomena when
breaking tolerance to self antigens [16]. In order to mini-
mize this risk, the immunotherapeutic community is con-
stantly looking for antigens which are tumor specific. The
most desired features an ideal target for active immu-
notherapy would have to posses, are (I) virtually exclusive
and (II) high density expression on the tumor cell, (III)
involvement in the tumorigenic process or in tumor pro-
gression (to minimize the risk of immune escape variants),
(IV) sufficient presentation in the form of MHC-bound
peptides to allow for accessibility by CTL and finally (V)
precursor T cells must be present in the T cell repertoire
after negative selection [[17,18] with modifications].
Taking these features into consideration, MRP and
MDR proteins completely fulfill the second and third
criteria since they are highly expressed as a consequence
of chemotherapy as described before. Moreover, Kuan et
al. identified MRP-3 as a molecular target in glioblas-
toma [19] and developed a recombinant single-chain
variable fragment antibody targeting MRP-3 [20]. Thus,
the last two criteria posed to tumor antigens may also
be met by MDR and MRP proteins.
Here, we took the classical reverse immunology
approach of bioinformatic HLA-A2.1-restricted peptide
prediction in combination with in vitro T cell stimula-
tion in an autologous setting to address the questions:
(I) can specific T cells be generated against several
MDR and MRP proteins and additionally (II) can color-
ectal cancer (CRC) cells expressing MDR or MRP pro-
teins be targeted by those T cells. We identified several
HLA-A2.1-restricted T cell epitopes including two
shared epitopes between two proteins and characterized
the antitumoral potential of the generated CTL lines.
Methods
Cell culture
Human CRC cell lines (SW480, SW707, HCT-116 and
Colo60H) and T2 cells (174 × CEM.T2 hybridoma, TAP1
and TAP2 deficient) were cultured in DMEM supple-
mented with 10% fetal calf serum, 2 mmol/L L-glutamine
and 1% penicillin-streptomycin and incubated at 37°C
and 5% CO2. All tumor cell lines were obtained from the
tumor bank of the DKFZ (Heidelberg, Germany) or from
the ATCC (Manassas, VA), media and supplements were
purchased from PAA (Cölbe, Germany).
CD40 ligand system for the culture of normal peripheral
blood B-cells
Culturing of CD40 ligand-activated B cells (CD40 B
cells) was performed as described [21]. Briefly, B cells
from peripheral blood mononuclear cells (PBMC) were
stimulated via NIH/3T3 cells stably expressing human
CD154 (t-CD154). Lethally irradiated t-CD154 (100 Gy)
were plated on 6-well plates (0.4 × 10
5 cells/well) and
cultured overnight. After rinsing with PBS, PBMC (2 ×
10
6 cells/ml) in Iscove’s MEM (Gibco BRL) supplemen-
ted with 10% human AB serum, 5 μg/ml insulin, 50 μg/
ml transferring and 15 μg/ml gentamicin were added
and cultured in the presence of IL-4 (2 ng/ml; Cellgenix,
Freiburg, Germany) and cyclosporin A (5.5 × 10
-7 M).
At intervals of 3 to 5 days, cells were transferred to new
plates containing fresh irradiated t-CD154 cells.
Peptides and HLA-A2.1-binding assay
The specific computer program SYFPEITHI [22] (access
via: http://www.syfpeithi.de) was applied to predict
peptides displaying HLA-A2.1-binding motifs from the
protein sequences of MDR and MRP proteins (MDPs; see
Table 1 for details). Peptides were purchased from the
peptide synthesis unit of the DKFZ. Stock solutions
(5 mg/ml in DMSO) were stored at -70°C and diluted to
500 μg/ml in PBS before use. T2 cells were pulsed with
10 μg/ml peptide and 5 μg/ml b2-microglobulin (Sigma,
Deisenhofen, Germany) overnight at 37°C. HLA-A2.1
expression was analysed by flow cytometry using MAb
BB7.2 followed by incubation with a FITC-conjugated goat
Ab binding anti-mouse Ig (Dako, Hamburg, Germany).
T-cell purification and induction of peptide-specific
cytotoxic T lymphocytes (CTL)
Whole CD3
+ T cells were isolated from PBMC by mag-
netic depletion of non T cells using the MACS Pan T Cell
Isolation Kit II (Miltenyi-Biotec, Bergisch Gladbach, Ger-
many) according to the manufacturer’si n s t r u c t i o n s .P r e -
parations contained at least 97% of CD3
+ cells as assessed
by immunophenotypic analysis. CD40 B cells of healthy
HLA-A2.1
+ donors were incubated with 10 μg/ml of dif-
ferent MDP-mixes (Table 2) in serum-free Iscove’s MEM
for 1 hr at room temperature, washed twice to remove
excess peptide, irradiated (30G y )a n da d d e dt op u r i f i e d
CD3
+ autologous T cells at a ratio of 1:4 (T-cells:CD40 B
cells) in Iscove’s MEM containing 10% human AB serum,
supplements (1:100) and hIL-7 (10 ng/ml, Cellgenix). T
cells were plated in 24-Well plates at a density of 2 × 10
6
T cells/well in 1 ml medium. After 3 days of culture 1 ml
complete medium was added. For T cell restimulation the
procedure was repeated on a weekly basis. IL-2 was added
at days 21 (10 IU/ml, Proleukine
®) and 24, and from day
28 on only hIL-2 was used.
Enzyme-linked immunospot (ELISpot) assay
ELISpot assays were performed as described before
[23]. Briefly, nitrocellulose 96-well plates (Multiscreen;
Millipore, Bedford, MA) were covered with mouse
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den) and blocked with medium containing serum.
Varying numbers of effector cells were plated in tripli-
cates with 3.5 × 10
4 peptide-loaded T2 cells per well
as targets. After incubation for 16 h, plates were
washed, incubated with biotinylated rabbit anti-human
INF-g secondary antibody, washed again, incubated
with streptavidin-coupled alkaline phosphatase, fol-
lowed by a final washing step. INF-g-secreting cells
were visualized by incubation with NBT/BCIP (Sigma)
























686-ALDESIPPV 29 2,07 0,61
MDP02
218-ILAISPVLGL 30 0,17 0,27
MDP03
858-LLLLAIVPII 27 0,96 0,17
MDP04
551-LLLDEATSAL 26 0,64 0,30
MDP05
850-FIYGWQLTLL 26 0,22 9,94 89,7
MDR-3 NM_018849 MDP04
551-LLLDEATSAL 26 0,64 0,30
MDP05
850-FIYGWQLTLL 26 0,22 9,94 89,7
MDP06
467-YLREIIGVV 28 0,13 0,60
MDP07
833-ALIAQNIANL 30 0,25 0,99 44,2
MDP08
860-LLAVVPIIAV 29 0,64 1,75 62,9
MRP-1 L05628 MDP09
1224-SLSAGLVGL 31 0,04 0,37
MDP10
452-ILALYLLWL 30 0,17 0,34
MDP11
745-ALLPDLEIL 30 0,61 0,52 88,2
MDP12
1109-LLATPIAAI 30 0,39 0,80
MDP13
118-LLATFLIQL 29 0,42 0,02
MDP14
508-ILNGIKVLKL 32 0,27 0,08
MDP15
461-NLGPSVLAGV 29 0,49 0,42 65,8
MDP16
466-VLAGVAVMVL 29 0,24 0,06
MRP-2 NM_000392 MDP17
661-IMAGQLVAV 31 0,42 0,04
MDP18
783-LLDDPLSAV 29 1,55 1,57 80,2
MDP19
42-LLAPWQLLHV 31 0,21 1,41 29,4
MDP20
77-ILAAIELALV 30 0,50 0,55
MDP21
782-YLLDDPLSAV 30 1,49 0,77
MRP-3 AF104943 MDP14
508-ILNGIKVLKL 32 0,27 0,08
MDP15
461-NLGPSVLAGV 29 0,49 0,42 65,8
MDP18
783-LLDDPLSAV 29 1,55 1,57 80,2
MDP22
1220-SLNPGLVGL 34 0,64 1,07
MDP23
1020-ILQGFLVML 31 1,33 0,47
MDP24
1082-VLAPVILML 30 1,98 0,50
MDP25
422-DLAPFLNLL 29 0,50 0,06
MDP26
1115-ILPLAVLYTL 29 0,23 0,18
MRP-5 XM_002914 MDP27
304-AILGMIYNV 29 1,09 0,37
MDP28
784-LLLGETPPV 29 1,35 0,67 24,9
MDP29





1 Protein or nucleotide accession numbers are indicated.
2 Position of the start amino acid in the protein is indicated.
3 Predicted binding scores to HLA-A2.1 using computer assisted analysis.
4 (Mean fluorescence with peptide-mean fluorescence without peptide)/(mean fluorescence without peptide).
5 Percentage of cells in the MDP-specific T cell bulk cultures secreting IFN-g upon stimulation with peptide-loaded T2 cells (maximum values observed over time
of stimulation).
6 Lysis of MDP-loaded T2 cells in % at an effector to target cell ratio of 100:1.
Results are representative of at least two experiments.
MDPs derived from more than one protein are listed twice with lighter shading when listed the second time.
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were counted.
Cytotoxicity assay
Cytotoxicity assays were performed as described before
[21]. Briefly, effector T cells were incubated in triplicate
in 96-well plates with
51Cr-labeled target cells at a ratio
of 3-100:1 (E:T). Cells were incubated for 4 h (T2 cells)
and 8 h (colorectal cancer cell lines) at 37°C. Plates
were centrifuged, and aliquots of the supernatants were
harvested and counted in a g-counter. Percent cytotoxi-
city was calculated as follows: 100% × (experimental
release-spontaneous release)/(maximal release-sponta-
neous release).
Induction of resistance towards chemotherapeutic agents
CRC cell lines were cultured as described above. For
augmentation of MDR and MRP protein expression on
the cell surface, cells were treated with 5-FU (500 ng/
ml-50 μg/ml), cisplatin (50 ng/ml-5 μg/ml) and a combi-
nation of both. MDR and MRP expression levels were
assessed with qPCR using the LightCycler
® technology
(Roche, Mannheim, Germany) as described [24,25].
Results
MDR and MRP-derived peptides
A total of thirty peptides displaying HLA-A2.1-binding
motifs were selected from the protein sequences of
MDR-1 and MDR-3, MRP-1, MRP-2, MRP-3 and MRP-
5 (MDPs; see Table 1 for details). Their binding capacity
to HLA-A2.1 was first tested in a functional binding
assay using T2 cells expressing HLA-A2.1 as the sole
MHC-molecule on their surface. Additionally, these
HLA-A2.1 molecules are devoid of bound endogenous
peptide due to a processing defect of the T2 cells.
Empty HLA molecules exhibit a rapid turnover and thus
T2 cells express only low levels of HLA-A2.1. Exogen-
ously added peptides can stabilize the HLA-A2.1
molecules and thus augment the HLA-A2.1 expression
levels assessed by flow cytometry. This is a good func-
tional measure for HLA-A2.1 binding capacity of pep-
tides [26]. As expected, the thirty MDPs displayed
varying HLA-A2.1-binding capacity. Details can be
depicted from Table 1.
Stimulation with MDP-mixes leads to CTL proliferation
Next feasibility of induction and antigen recognition of
MDP-specific CTL should be determined. Therefore,
PBMC of two healthy donors were used to isolate T
cells and to generate CD40 B cells. The latter were
loaded with MDPs in different mixes and used for sti-
mulation of autologous T cells. T cell proliferation rates
were determined over time (donor 1: Figure 1A; donor
2: Figure 1B). Stimulations using the influenza matrix
peptide MP (positive control) and the P68 peptide
(negative control) were additionally performed for donor
1 and served as controls (Figure 1A). All of these condi-
tions clearly resulted in sustained T cell proliferation,
with MDP mix 1 (donor 1: Figure 1A) and MDP mix 3
(donor 2: Figure 1B) inducing the highest proliferation.
Outgrowing T cell cultures were predominantly CD8
+
(data not shown).
IFN-g producing CTL are induced by MDP stimulation
The rate of peptide specific stimulation was investigated
by IFN-g-ELISpot analyses. T2 cells were loaded with
Table 2 Composition of the MDP mixes used for bulk T
cell stimulation






















1 MDR or MRP protein the listed MDP originates from MDP representing
epitopes shared between two MDR or MRP proteins are underlined.
(a)
(b)
Figure 1 Growth of MDP-Peptide-Mix stimulated T cells.T h e
outgrowth of MDP-stimulated T cells was assessed by counting the
number of viable T cells weekly and calculating an accumulated
growth factor. T cell cultures were generated from two healthy
donors; (A) donor 1 and (B) donor 2.
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(either single peptides or as mixes) and served as targets
for the IFN-g-ELISpot analyses. Significant numbers of
IFN-g secreting T cells could be detected and therefore
hint towards a strong reactivity against several peptides
for both donors (Figure 2 and Table 1). In summary,
peptide mixes 1, 2, 4, 5 and 6 led to IFN-g producing
CTL with a total of 14 MDPs being recognized by more
than 0.5% of the T cells in the respective cultures. The
greatest effects were seen with MDP mixes 1 and 4 for
donor 1 and peptide mixes 1 and 5 for donor 2. When
looking at the single peptide levels MDP05 (mix 1),
MDP08 (mix 2) and MDP29 (mix 4) for donor 1 and
MDP05 (mix 1) and MDP18 and 19 (mix 5) for donor 2
provoked the strongest reactions (Figure 2 and Table 1).
MDP-specific T cells have strong cytolytic potential
IFN-g production is a clear sign of specific activation. It
d o e s ,h o w e v e r ,n o tp r o v ec y t otoxic ability. Therefore,
we next tested the potential of the induced CTL to kill
peptide-loaded T2 target cells. Here, we observed effi-
cient target cell killing when peptides used for T cell
stimulation and target cell loading matched (Figure 3
and Table 1). We observed no reactivity above ten per-
cent background when irrelevant peptide was loaded
onto the T2 targets (data not shown). Overall, the
results of ELISpot and cytotoxicity tests showed a high
degree of accordance. However, two details are remark-
able: (i) despite relatively few IFN-g producing CTL
upon cognate stimulation with MDP11 (donor 2;
0.52%), there was a comparably high reactivity observed
in the cytotoxicity test and (ii) in contrast, approxi-
mately 1.4% donor 2 mix-5 stimulated T cells secreted
IFN-g upon stimulation with MDP19 but they did only
marginally lyse MDP19-loaded T2 targets (Figure 2B
and Figure 3).
MDP-specific CTL lyse tumor cells
The ability to kill tumor cells endogenously expressing
the target peptides is the final goal of the reverse immu-
nology approach. We thus analyzed in further cytotoxi-
city tests, whether MDP-specific CTL really attack
tumor cells. The target tumor cells were pretreated with
increasing doses of cisplatin and 5-FU in vitro (data not
shown). Then, cultures showing high level expression of
MDR and MRP were chosen as target cells. Here, tumor
cell lysis rates of up to 8% could be achieved for the
HLA-A2.1
+ cell line SW480 and CTL specific for MDP-
mix 1 (Figure 4 and 4B). Respectively lysis rates of up to
1 7 %f o rM D P - m i x3a n d5 %f o rM D P - m i x5c o u l db e
obtained (data not shown). However, these were the
strongest reactions observed; even lower levels of tumor
cell killing were found for other HLA-A2.1
+ target cell
lines (HCT116, SW707 and Colo60H).
In summary, the observed cytotoxic effects were rather
low.
Discussion
Physiologically, MDR and MRP proteins are expressed
in a variety of human tissues including liver, kidney and
the blood-brain-barrier [[27] and [28]]. Considering
their function as membrane transporters with the ability
to transport different substances against concentration
gradients their function obviously lies-at least to a
greater proportion-in cellular detoxification [[27] and
[28]]. Of note, it has been suggested that MDR and
MRP proteins are expressed particularly in tissue stem
cells and thus protect those precious cells from damage
[4].
When looking at tumor, the expression of MDR and
MRP proteins has been reported for malignant cells of
different entities [29]. Clinical data prove that their
expression is upregulated as an attempt to acquire resis-
tance towards the effects of chemotherapeutic agents in
the cause of chemotherapy [30]. To us, this phenom-
enon is in perfect accordance with the observation that
tumor cells contain properties of the tissue stem cell
they originate from, mainly unlimited life span, resis-
tance towards apoptosis and cellular plasticity [31].
This detailed mechanistic understanding of the MDR
and MRP protein function in malignant cells suggests
those proteins as perfect targets for the development of
novel therapeutical approaches. Beside classical drugs,
small molecules and therapeutical antibodies, immu-
notherapeutic strategies steadily gain more clinical rele-
vance. A magnitude of immunological target proteins
relevant for tumorigenesis and maintenance of the
transformed state have been identified so far. Those
include Her2/neu, bcr/abl, WT-1, survivin and hTERT
[8,32-35]. Nakai et al. correlated enhanced MDR-1
expression with chemoresistance of cancer stem cells
derived from glioblastoma and suggested MDR-1 as an
immunotherapeutic target [29]. Kuan and coworkers
suggested MRP-3 as a potential immunotherapeutic tar-
get for glioblastoma [19]. They subsequently even devel-
oped a specific therapeutic antibody [20]. Clinical
testings have, however, not yet been reported. Similarly,
Yamada et al. identified MRP-3 as a true tumor rejec-
tion antigen when analyzing the target structure of a
cytotoxic T cell clone isolated from a human lung can-
cer patient [36].
Taking these considerations as a starting point, we
chose the classical in silico prediction to identify MDR
and MRP-derived T cell epitopes restricted to HLA-
A2.1 since this is the most frequent HLA allele in the
Caucasian population. A comprehensive number of epi-
tope peptides was selected and subsequently tested for
immunostimulatory potential. This has, to the best of
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Figure 2 ELISpot analysis of MDP-specific IFN-g release. The percentage of T cells secreting IFN-g in response to MDP-loaded target cells was
determined in a series of ELISpot experiments. Reactivity for MDP-stimulated T cells of (A) donor 1 (exemplarily for day 77) and (B) donor 2
(exemplarily for day 77) is given. Analysis was performed in triplicates with 1.000 effector and 10.000 target cells per well.
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was performed in mixed-lymphocyte-peptide cultures
with T cells from two healthy individuals. Satisfactory
growth of T cell cultures in vitro was observed. Pheno-
typical analysis revealed the outgrowth of predominantly
CD8
+ CTL. Subsequent functional testing could identify
reactivity against twelve peptides out of thirty tested
MDPs. MDR and MRP-specific CTL recognized their
epitopes in IFN-g ELISpots and in cytotoxicity tests
using peptide-loaded HLA-A2.1
+ target cells. Of note,
we obtained CTL specific for epitopes derived from all
MDR and MRP proteins included into the analysis,
namely MDR-1, MDR-3, MRP-1, MRP-2, MRP-3 and
MRP-5. Strikingly, two of the epitopes are shared
between MDR-1 and MDR-3 (MDP05) as well as MRP-
2 and MRP-3 (MDP18), which may be of special interest
for future immunological analysis.
Collectively, this allows the conclusion that the human
immune system harbors HLA-A2.1-restricted T cells
specifically recognizing MDR and MRP-derived peptides.
Additionally, it is in line with the previous description of
HLA-A24-restricted T cells specific for MRP-3 [36]. The
combination of these studies leads to the conclusion
that no absolute central and peripheral tolerance seems
to exist for MDR and MRP proteins.
However, when testing the CTL’s potential to kill
tumor cell lines expressing high levels of MDR and
MRP proteins, the level of tumor cell recognition was
disappointingly low in the present study. This may best
be explained by insufficient or missing processing of
MDR and MRP-proteins by the cellular proteasomal
machinery or similarly by insufficient or missing presen-
tation in the context of HLA-A2.1 molecules. Our
screen was limited to HLA-A2.1, and consequently
MDR and MRP-derived peptides may be presented in
high levels in other HLA-molecules. Moreover, our find-
ings are to some extent in contrast to the observations
of Yamada et al. They could activate T cells with MRP-
3 derived peptides in an HLA-A24 restricted manner
and further observed a specific lysis of lung cancer cells




































Figure 3 Analysis of MDP-specific CTL activity against peptide-
sensitized T2 target cells. Cytotoxic activity of MDP-specific CTL
after at least 3 rounds of restimulation with the indicated MDP
mixes was analyzed in standard
51Cr-release assays. MDP-specific
reactivity of T cell bulk cultures (Mix-1Tc to Mix-6Tc) was tested
against T2 target cells loaded with either the indicated peptide
mixes or the given individual MDP. Effector T cells were added at
different effector to target cell (E:T) ratios. A representative
experiment with CTL derived from donor 2 is shown. The analysis
was performed in triplicates with 1.000 effector cells per well and
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Figure 4 Analysis of MDP-specific CTL activity against CRC cell
lines. Standard
51Cr-release cytotoxicity assays were performed with
MDP05-specific CTL using CRC cell lines as target cells. Effector T
cells were added at different effector to target cell (E:T) ratios. A
representative experiment of CTL derived from (A) donor 1 and (B)
donor 2 is shown. Analysis was performed in triplicates with 1.000
effector cells per well and after a 6 h incubation period. The
expression levels of MDR-1 and MDR-3 are given as additional
information (right upper corner) for untreated SW480 and SW707
and for cisplatin and 5-FU pretreated SW480 in copies/μl cDNA
normalized to the housekeeping genes cyclophilin B and
hypoxanthine guanine phosphoribosyltransferase.
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killing (approximately 15% at an E:T ratio of 100:1) and
since our screen was limited to CRC cell lines, this may
hint towards comparably bad processing and presenta-
tion of MDR and MRP proteins in CRC cells. Intrinsic
resistance towards CTL lysis of the CRC cell lines used
in our study can be excluded, since we successfully used
them as CTL targets before [21,23]. A speculative
hypothesis is that this may be the result of previous
immunoediting of the colorectal cancer cells. This
would imply a high relevance of MDR and MRP as
tumor specific antigens in the natural course of host
and tumor immune interaction but would clearly limit
the usefulness of HLA-A2.1-restricted peptides for clini-
cal immunotherapy.
Conclusion
MDR and MRP-derived peptides can give rise to com-
pletely functional CTL out of the human repertoire.
Killing of CRC tumor cells was however only marginally.
This does not recommend the targeting of MDR and
MRP proteins as solitary tumor antigens in immu-
notherapeutic interventions BUT because of their ther-
apy-related up regulated expression they may well be
considered as add-on in multi-epitope immunotherapies.
This must be assessed in future studies. Yet, they may
be perfect tumor antigens for other tumor entities.
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